A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2023; you can also visit the original URL.
The file type is application/pdf
.
Rheumatoid factor and antibodies against cyclic citrullinated peptide in patients without rheumatoid arthritis
2023
Klinicist
A review of data on the possible causes of an increase rheumatoid factor (RF), antibodies against cyclic citrullinated peptide (ACCP) and antibodies to modified citrullinated vimentin (AMCV) in patients without rheumatoid arthritis (RA) is presented. The possibility of hyperproduction of these autoantibodies before the development of the clinical picture of RA was indicated. It is indicated that ACCP and IgA RF have the greatest prognostic value in terms of the subsequent development of RA.
doi:10.17650/1818-8338-2022-16-3-k669
fatcat:pgrm4fywe5dmfk3vbx24gmbg24